Innovate Retina

Presented by the Stanford Medicine – Byers Eye Institute

Thursday, November 2, 2023 – In-Person

Innovate Retina 2023

New Dates coming Soon!

Statement of Need

The Innovate Retina series will continue in 2023, dates will be announced soon.

The meetings will focus exclusively on game-changing innovations in medical and surgical retina care, including current management of age-related macular degeneration (AMD) and diabetic retinopathy, ocular imaging, gene therapy, ocular inflammation, surgical technologies, ocular oncology, and the latest advances in retinal pharmacotherapy.


Topics will include late breaking retina pharmacotherapy clinical trials data, current management of neovascular AMD, diabetic macular edema, and diabetic retinopathy, updates on artificial intelligence (AI) for diagnosis, advances in molecular surgery for the precision treatment of previously untreatable blinding diseases, and novel drug delivery technologies designed to improve patient care. We will also focus on the role of imaging in determining new biomarkers for disease. Surgical innovation will be addressed in terms of new instrumentation, visualization enhancements, and imageā€“guided surgery.

Educational Objectives

At the conclusion of this activity, participants will be able to:

  • Identify current management of common retinal vascular diseases including wet AMD, diabetic macular edema, and diabetic retinopathy
  • Discuss the efficacy, safety, and treatment regimens of current and new anti-VEGF agents (including sustained delivery devices, dual inhibitors, and extended durability VEGF inhibitors), in wet AMD, diabetic macular edema, and diabetic retinopathy including long-acting formulations
  • Discuss unmet needs in the management of retinal vascular diseases including radiation retinopathy
  • Learn more about the impact of retinal diseases seen in diverse ethnic populations such as high myopia, polypoidal choroidal vasculopathy, and pachychoroiod syndromes.
  • Assess innovations across imaging, medical devices, artificial intelligence, and pharmacotherapeutics
  • Examine the latest clinical data on emerging pharmacotherapeutics in the retina
  • Evaluate key gene therapy trials for macular and inherited retinal diseases and develop strategies for managing inflammation in these patients
  • Integrate novel surgical imaging systems into clinical practice

Target Audience

Practicing retina specialists, retinal fellows in training, and vitreoretinal surgeons. Comprehensive ophthalmologists, vision and AI scientists in retina, translational scientists, oncologists and allied physicians, and imaging experts are encouraged to attend.